SLNO - Soleno Therapeutics Inc Profit before interest, taxes and amortization
The positive trend, driven by triumphant trials and physician confidence, confirms the absolute cash result of operations, where the 91.30 mark records this metric for Soleno Therapeutics (SLNO). Growth is based on the commercialization of therapy for Prader-Willi syndrome; however, development is constrained by strict FDA oversight, high R&D costs, and patent complexities associated with entering the rare orphan drug market.
Summary analytical data breakdowns for soleno.life (SLNO)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization data:
- company total debt and liquidity indicators:
Debt to Equity Soleno Therapeutics|SLNO - Long-Term Debt to Equity|Current Liabilities to Capital Soleno Therapeutics Corp|SLNO - Company Debts|Debt to Book Capitalization Ratio Soleno Therapeutics, Inc.|SLNO - Company Long-Term Debts|Short-Term Debt Volume Soleno Therapeutics|Interim Coverage Ratio soleno.life
- financial results and valuation multiples details:
SLNO - Company Net Income|Future Profit Soleno Therapeutics|SLNO - Price to Earnings Ratio|Market Cap to Projected Earnings Soleno Therapeutics Inc|SLNO - Price/Earnings to Growth Ratio|Company Value to EBITDA Soleno Therapeutics Inc|SLNO - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Soleno Therapeutics|SLNO - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months soleno.life|SLNO - Earnings per share growth in current year|Projected earnings per share growth rate for next year Soleno Therapeutics
- sales revenue and business income indicators:
Analysis of all company metrics:Soleno Therapeutics (SLNO)
For the biotech sector, where Soleno Therapeutics (SLNO) depends on external financing and regulatory decisions, the company's EBITDA statistics serve as an indicator of actual cash flow from operating activities, excluding paper adjustments. This metric allows investors to track the burn rate in real time and identify cash gaps long before the publication of official financial statements.
Who Soleno Therapeutics competes with
ASND - Operating profit before deduction of amortization|Madrigal Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Corcept|RYTM (Rhythm Pharmaceuticals, Inc.) - Operating profit before deduction of amortization|AKRO: Company profit before taxes, interest and amortization|MTSR (Metsera Therapeutics) - Operating profit EBITDA|Operating profit EBITDA MoonLake Immunotherapeutics|Operating profit EBITDA CRNX|Profit before payment of interest, taxes and amortization NAMS (NewAmsterdam Pharma Company)|Profit before payment of interest, taxes and amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Profit before interest, taxes and amortization|AGIO - Profit before payment of interest, taxes and amortization|GPCR: Profit before payment of interest, taxes and amortization|MDXG: Operating profit EBITDA|RZLT - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Lexicon Corp|Operating profit before deduction of amortization MBX Corp (MBX)|Operating profit EBITDA ALT|Operating profit before deduction of amortization Aardvark Therapeutics Inc AARD|Profit before payment of interest, taxes and amortization Sagimet Biosciences, Inc. SGMT|BioAge - Profit before payment of interest, taxes and amortization|Biomea Fusion Corp - Operating profit EBITDA|QNCX - Operating profit EBITDA|GUTS: Operating profit EBITDA|VTVT (vTv Therapeutics Inc.) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Agape ATP Corp.|PLUR: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Synlogic, Inc. (SYBX)|Operating profit before deduction of amortization Lipocine Corp LPCN|Operating profit EBITDA MTNB (Matinas BioPharma Holdings, Inc.)|Spruce Biosciences (SPRB) - Profit before interest, taxes and amortization|GLTO - Profit before payment of interest, taxes and amortization|CTCX: Profit before payment of interest, taxes and amortization|LUMO: Operating profit EBITDA|Profit before interest, taxes and amortization Organovo Holdings, Inc. (ONVO)|RDUS (Radius Recycling Inc.) - Operating profit EBITDA
